YOKOHAMA, Japan, June 25, 2025 (AGC Biologics) — AGC Biologics announced the expansion of its Global Cell and Gene Technologies Division, launching cell therapy process development and clinical manufacturing at its Yokohama Technical Center.
The facility will support autologous and allogeneic therapies, utilizing technologies like CAR-T and stem cell therapies, serving the growing Asian market. This complements existing sites in Milan, Italy, and Longmont, Colorado. A new Yokohama manufacturing facility, set for 2027, will offer pre-clinical to commercial services. The Milan Center of Excellence, with nine EMA/FDA approvals, will aid the Yokohama site’s ramp-up. ‘Asian developers can benefit from a local supply within one of the best global infrastructures,’ said Luca Alberici, EVP of Global Cell and Gene Technologies.
Read the full article on agcbio.com
Share this page on social